Literature DB >> 26801895

Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet.

Michael A Rogawski1, Wolfgang Löscher2, Jong M Rho3.   

Abstract

Antiseizure drugs (ASDs), also termed antiepileptic drugs, are the main form of symptomatic treatment for people with epilepsy, but not all patients become free of seizures. The ketogenic diet is one treatment option for drug-resistant patients. Both types of therapy exert their clinical effects through interactions with one or more of a diverse set of molecular targets in the brain. ASDs act by modulation of voltage-gated ion channels, including sodium, calcium, and potassium channels; by enhancement of γ-aminobutyric acid (GABA)-mediated inhibition through effects on GABAA receptors, the GABA transporter 1 (GAT1) GABA uptake transporter, or GABA transaminase; through interactions with elements of the synaptic release machinery, including synaptic vesicle 2A (SV2A) and α2δ; or by blockade of ionotropic glutamate receptors, including α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptors. The ketogenic diet leads to increases in circulating ketones, which may contribute to the efficacy in treating pharmacoresistant seizures. Production in the brain of inhibitory mediators, such as adenosine, or ion channel modulators, such as polyunsaturated fatty acids, may also play a role. Metabolic effects, including diversion from glycolysis, are a further postulated mechanism. For some ASDs and the ketogenic diet, effects on multiple targets may contribute to activity. Better understanding of the ketogenic diet will inform the development of improved drug therapies to treat refractory seizures.
Copyright © 2016 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26801895      PMCID: PMC4852797          DOI: 10.1101/cshperspect.a022780

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  190 in total

1.  Nav1.1 modulation by a novel triazole compound attenuates epileptic seizures in rodents.

Authors:  John Gilchrist; Stacey Dutton; Marcelo Diaz-Bustamante; Annie McPherson; Nicolas Olivares; Jeet Kalia; Andrew Escayg; Frank Bosmans
Journal:  ACS Chem Biol       Date:  2014-03-31       Impact factor: 5.100

2.  Levetiracetam accelerates the onset of supply rate depression in synaptic vesicle trafficking.

Authors:  Elizabeth García-Pérez; Kashif Mahfooz; João Covita; Aitor Zandueta; John F Wesseling
Journal:  Epilepsia       Date:  2015-02-16       Impact factor: 5.864

Review 3.  Low threshold T-type calcium channels as targets for novel epilepsy treatments.

Authors:  Kim L Powell; Stuart M Cain; Terrance P Snutch; Terence J O'Brien
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

Review 4.  The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments.

Authors:  Rafal M Kaminski; Michael A Rogawski; Henrik Klitgaard
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

Review 5.  Treatment of infantile spasms: emerging insights from clinical and basic science perspectives.

Authors:  Carl E Stafstrom; Barry G W Arnason; Tallie Z Baram; Anna Catania; Miguel A Cortez; Tracy A Glauser; Michael R Pranzatelli; Raili Riikonen; Michael A Rogawski; Shlomo Shinnar; John W Swann
Journal:  J Child Neurol       Date:  2011-06-30       Impact factor: 1.987

Review 6.  The on-off switches of the mitochondrial uncoupling proteins.

Authors:  Vian Azzu; Martin D Brand
Journal:  Trends Biochem Sci       Date:  2009-12-16       Impact factor: 13.807

7.  Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor.

Authors:  Tadahiro Shimazu; Matthew D Hirschey; John Newman; Wenjuan He; Kotaro Shirakawa; Natacha Le Moan; Carrie A Grueter; Hyungwook Lim; Laura R Saunders; Robert D Stevens; Christopher B Newgard; Robert V Farese; Rafael de Cabo; Scott Ulrich; Katerina Akassoglou; Eric Verdin
Journal:  Science       Date:  2012-12-06       Impact factor: 47.728

8.  Neuronal-glial interactions in rats fed a ketogenic diet.

Authors:  Torun Margareta Melø; Astrid Nehlig; Ursula Sonnewald
Journal:  Neurochem Int       Date:  2006-03-20       Impact factor: 3.921

9.  The ketogenic diet increases mitochondrial glutathione levels.

Authors:  Stuart G Jarrett; Julie B Milder; Li-Ping Liang; Manisha Patel
Journal:  J Neurochem       Date:  2008-05-05       Impact factor: 5.372

10.  Levetiracetam but not valproate inhibits function of CD8+ T lymphocytes.

Authors:  Gang Li; Mareike Nowak; Sebastian Bauer; Kerstin Schlegel; Susanne Stei; Lena Allenhöfer; Anne Waschbisch; Björn Tackenberg; Matthias Höllerhage; Günter U Höglinger; Sven Wegner; Xin Wang; Wolfgang H Oertel; Felix Rosenow; Hajo M Hamer
Journal:  Seizure       Date:  2013-04-29       Impact factor: 3.184

View more
  59 in total

Review 1.  Metabolism and epilepsy: Ketogenic diets as a homeostatic link.

Authors:  Susan A Masino; Jong M Rho
Journal:  Brain Res       Date:  2018-06-06       Impact factor: 3.252

Review 2.  Intermittent metabolic switching, neuroplasticity and brain health.

Authors:  Mark P Mattson; Keelin Moehl; Nathaniel Ghena; Maggie Schmaedick; Aiwu Cheng
Journal:  Nat Rev Neurosci       Date:  2018-01-11       Impact factor: 34.870

Review 3.  Do ketone bodies mediate the anti-seizure effects of the ketogenic diet?

Authors:  Timothy A Simeone; Kristina A Simeone; Carl E Stafstrom; Jong M Rho
Journal:  Neuropharmacology       Date:  2018-01-08       Impact factor: 5.250

4.  Glycolytic inhibitor 2-deoxyglucose prevents cortical hyperexcitability after traumatic brain injury.

Authors:  Jenny B Koenig; David Cantu; Cho Low; Mary Sommer; Farzad Noubary; Danielle Croker; Michael Whalen; Dong Kong; Chris G Dulla
Journal:  JCI Insight       Date:  2019-04-30

Review 5.  Epigenetics and epilepsy prevention: The therapeutic potential of adenosine and metabolic therapies.

Authors:  Detlev Boison; Jong M Rho
Journal:  Neuropharmacology       Date:  2019-08-13       Impact factor: 5.250

Review 6.  Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics.

Authors:  Patrycja Puchalska; Peter A Crawford
Journal:  Cell Metab       Date:  2017-02-07       Impact factor: 27.287

Review 7.  Ketone Bodies as Anti-Seizure Agents.

Authors:  Timothy A Simeone; Kristina A Simeone; Jong M Rho
Journal:  Neurochem Res       Date:  2017-04-10       Impact factor: 3.996

Review 8.  Adenosine and Ketogenic Treatments.

Authors:  David N Ruskin; Masahito Kawamura; Susan A Masino
Journal:  J Caffeine Adenosine Res       Date:  2020-09-16

Review 9.  Cerebral Metabolic Changes During Sleep.

Authors:  Nadia Nielsen Aalling; Maiken Nedergaard; Mauro DiNuzzo
Journal:  Curr Neurol Neurosci Rep       Date:  2018-07-16       Impact factor: 5.081

Review 10.  Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options.

Authors:  Wolfgang Löscher; Heidrun Potschka; Sanjay M Sisodiya; Annamaria Vezzani
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.